XOLAIR® (Omalizumab) is an immunosuppressive drug used to treat moderate to severe persistent allergic asthma not controlled by inhaled corticosteroids and chronic idiopathic urticaria not controlled by H1 antihistamines.
XOLAIR® is manufactured by Genentech/Novartis.
Administration and Dosage:
Administration of XOLAIR is a subcutaneous injection every 2 or 4 weeks.
Common Side Effects:
The more common side effects of XOLAIR® include cancer, inflammation of blood vessels, parasite infection, heart and circulation problems, and fever, muscle aches, and rash.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
XOLAIR® is indicated to treat:
- Moderate to Severe Persistent Allergic Asthma
- Chronic Idiopathic Urticaria